GS vs TERN · P/E 20, $324.25B cap vs $6.12B cap
Goldman Sachs Group Inc (GS) versus Terns Pharmaceuticals Inc (TERN) — a side-by-side from cached financials, not a winner call.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Terns Pharmaceuticals Inc (TERN) is a biotechnology company listed on NASDAQ.
GS does not have a complete income-statement cache yet.
Latest reported TERN revenue for 2022-12-31 was $0. Net income was -$60.3M. TERN currently screens at market cap $6.12B.
GS currently screens at market cap $324.25B and trailing P/E 20.1. TERN currently screens at market cap $6.12B.
Not investment advice. Open the GS and TERN stock pages for the full models.
Not investment advice.